Execs On The Move: Expert CMOs Appointed At Newronika, Relay And Savara
Italian medical research services firm Newronika, developer of protein motion drug discovery Relay Therapeutics, and orphan lung disease company Savara have selected expert physician-scientist CMOs to lead their investigational programs; and more.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.